Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
41
SLS Quote, Financials, Valuation and Earnings
Last price:
$4.14
Seasonality move
:
5.98%
Day range:
$4.02 - $4.20
52-week range:
$0.95 - $6.14
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
10.47x
Volume:
4.8M
Avg. volume:
8.1M
1-year change:
278.9%
Market cap:
$728.5M
Revenue:
--
EPS (TTM):
-$0.25
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SLS
SELLAS Life Sciences Group, Inc.
|
-- | -$0.06 | -- | -9.37% | $8.67 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$283.1M | $0.07 | 16.03% | -30.17% | $31.85 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.1B | $1.53 | 88.89% | -58.59% | $449.32 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$754.8M | $1.00 | 3.04% | 4.71% | $88.87 |
|
IMNN
Imunon, Inc.
|
-- | -$1.27 | -- | -60.16% | $21.50 |
|
SVRA
Savara, Inc.
|
-- | -$0.14 | -- | -12.28% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SLS
SELLAS Life Sciences Group, Inc.
|
$4.13 | $8.67 | $728.5M | -- | $0.00 | 0% | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.20 | $31.85 | $3.8B | 9.65x | $0.00 | 0% | 3.49x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$318.85 | $449.32 | $41B | 141.27x | $0.00 | 0% | 11.46x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$55.50 | $88.87 | $10.3B | 31.15x | $0.00 | 0% | 3.33x |
|
IMNN
Imunon, Inc.
|
$3.22 | $21.50 | $7.4M | -- | $0.00 | 0% | 16.43x |
|
SVRA
Savara, Inc.
|
$5.56 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SLS
SELLAS Life Sciences Group, Inc.
|
1.39% | -1.177 | 0.17% | 10.25x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 2.895 | 1.15% | 3.40x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.662 | 5.64% | 2.51x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.55% | -0.343 | 5.63% | 3.25x |
|
IMNN
Imunon, Inc.
|
21.26% | 7.808 | 10.13% | 1.25x |
|
SVRA
Savara, Inc.
|
12.84% | -1.345 | 2.43% | 11.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SLS
SELLAS Life Sciences Group, Inc.
|
-- | -$8.3M | -72.97% | -74.67% | -- | -$4.9M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$614.5M | $99.8M | 5.33% | 5.89% | 11.16% | $56.6M |
|
IMNN
Imunon, Inc.
|
-$167K | -$3.5M | -282.76% | -365% | -- | -$4.4M |
|
SVRA
Savara, Inc.
|
-$40K | -$33.4M | -67.27% | -80.59% | -- | -$25.1M |
SELLAS Life Sciences Group, Inc. vs. Competitors
-
Which has Higher Returns SLS or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to SELLAS Life Sciences Group, Inc.'s net margin of 96.33%. SELLAS Life Sciences Group, Inc.'s return on equity of -74.67% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital SLSSELLAS Life Sciences Group, Inc.-- -$0.05 $71.9M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About SLS or ACAD?
SELLAS Life Sciences Group, Inc. has a consensus price target of $8.67, signalling upside risk potential of 109.85%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.85 which suggests that it could grow by 43.47%. Given that SELLAS Life Sciences Group, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe SELLAS Life Sciences Group, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLSSELLAS Life Sciences Group, Inc.2 0 0 ACADACADIA Pharmaceuticals, Inc.12 4 1 -
Is SLS or ACAD More Risky?
SELLAS Life Sciences Group, Inc. has a beta of 2.225, which suggesting that the stock is 122.467% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.833, suggesting its less volatile than the S&P 500 by 16.67%.
-
Which is a Better Dividend Stock SLS or ACAD?
SELLAS Life Sciences Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SELLAS Life Sciences Group, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLS or ACAD?
SELLAS Life Sciences Group, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. SELLAS Life Sciences Group, Inc.'s net income of -$7.7M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, SELLAS Life Sciences Group, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 9.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SELLAS Life Sciences Group, Inc. is -- versus 3.49x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLSSELLAS Life Sciences Group, Inc.-- -- -- -$7.7M ACADACADIA Pharmaceuticals, Inc.3.49x 9.65x $284M $273.6M
-
Which has Higher Returns SLS or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to SELLAS Life Sciences Group, Inc.'s net margin of 16.99%. SELLAS Life Sciences Group, Inc.'s return on equity of -74.67% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital SLSSELLAS Life Sciences Group, Inc.-- -$0.05 $71.9M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About SLS or ALNY?
SELLAS Life Sciences Group, Inc. has a consensus price target of $8.67, signalling upside risk potential of 109.85%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $449.32 which suggests that it could grow by 40.92%. Given that SELLAS Life Sciences Group, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe SELLAS Life Sciences Group, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLSSELLAS Life Sciences Group, Inc.2 0 0 ALNYAlnylam Pharmaceuticals, Inc.14 8 0 -
Is SLS or ALNY More Risky?
SELLAS Life Sciences Group, Inc. has a beta of 2.225, which suggesting that the stock is 122.467% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.387, suggesting its less volatile than the S&P 500 by 61.27%.
-
Which is a Better Dividend Stock SLS or ALNY?
SELLAS Life Sciences Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SELLAS Life Sciences Group, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLS or ALNY?
SELLAS Life Sciences Group, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. SELLAS Life Sciences Group, Inc.'s net income of -$7.7M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, SELLAS Life Sciences Group, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 141.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SELLAS Life Sciences Group, Inc. is -- versus 11.46x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLSSELLAS Life Sciences Group, Inc.-- -- -- -$7.7M ALNYAlnylam Pharmaceuticals, Inc.11.46x 141.27x $1.1B $186.4M
-
Which has Higher Returns SLS or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -- compared to SELLAS Life Sciences Group, Inc.'s net margin of -5.2%. SELLAS Life Sciences Group, Inc.'s return on equity of -74.67% beat BioMarin Pharmaceutical, Inc.'s return on equity of 5.89%.
Company Gross Margin Earnings Per Share Invested Capital SLSSELLAS Life Sciences Group, Inc.-- -$0.05 $71.9M BMRNBioMarin Pharmaceutical, Inc.68.65% -$0.24 $6.7B -
What do Analysts Say About SLS or BMRN?
SELLAS Life Sciences Group, Inc. has a consensus price target of $8.67, signalling upside risk potential of 109.85%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.87 which suggests that it could grow by 60.13%. Given that SELLAS Life Sciences Group, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe SELLAS Life Sciences Group, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLSSELLAS Life Sciences Group, Inc.2 0 0 BMRNBioMarin Pharmaceutical, Inc.14 5 0 -
Is SLS or BMRN More Risky?
SELLAS Life Sciences Group, Inc. has a beta of 2.225, which suggesting that the stock is 122.467% more volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.293, suggesting its less volatile than the S&P 500 by 70.697%.
-
Which is a Better Dividend Stock SLS or BMRN?
SELLAS Life Sciences Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SELLAS Life Sciences Group, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLS or BMRN?
SELLAS Life Sciences Group, Inc. quarterly revenues are --, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $895M. SELLAS Life Sciences Group, Inc.'s net income of -$7.7M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$46.6M. Notably, SELLAS Life Sciences Group, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 31.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SELLAS Life Sciences Group, Inc. is -- versus 3.33x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLSSELLAS Life Sciences Group, Inc.-- -- -- -$7.7M BMRNBioMarin Pharmaceutical, Inc.3.33x 31.15x $895M -$46.6M
-
Which has Higher Returns SLS or IMNN?
Imunon, Inc. has a net margin of -- compared to SELLAS Life Sciences Group, Inc.'s net margin of --. SELLAS Life Sciences Group, Inc.'s return on equity of -74.67% beat Imunon, Inc.'s return on equity of -365%.
Company Gross Margin Earnings Per Share Invested Capital SLSSELLAS Life Sciences Group, Inc.-- -$0.05 $71.9M IMNNImunon, Inc.-- -$1.16 $5.2M -
What do Analysts Say About SLS or IMNN?
SELLAS Life Sciences Group, Inc. has a consensus price target of $8.67, signalling upside risk potential of 109.85%. On the other hand Imunon, Inc. has an analysts' consensus of $21.50 which suggests that it could grow by 567.7%. Given that Imunon, Inc. has higher upside potential than SELLAS Life Sciences Group, Inc., analysts believe Imunon, Inc. is more attractive than SELLAS Life Sciences Group, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLSSELLAS Life Sciences Group, Inc.2 0 0 IMNNImunon, Inc.3 1 0 -
Is SLS or IMNN More Risky?
SELLAS Life Sciences Group, Inc. has a beta of 2.225, which suggesting that the stock is 122.467% more volatile than S&P 500. In comparison Imunon, Inc. has a beta of 2.127, suggesting its more volatile than the S&P 500 by 112.653%.
-
Which is a Better Dividend Stock SLS or IMNN?
SELLAS Life Sciences Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Imunon, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SELLAS Life Sciences Group, Inc. pays -- of its earnings as a dividend. Imunon, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLS or IMNN?
SELLAS Life Sciences Group, Inc. quarterly revenues are --, which are smaller than Imunon, Inc. quarterly revenues of --. SELLAS Life Sciences Group, Inc.'s net income of -$7.7M is lower than Imunon, Inc.'s net income of -$3.4M. Notably, SELLAS Life Sciences Group, Inc.'s price-to-earnings ratio is -- while Imunon, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SELLAS Life Sciences Group, Inc. is -- versus 16.43x for Imunon, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLSSELLAS Life Sciences Group, Inc.-- -- -- -$7.7M IMNNImunon, Inc.16.43x -- -- -$3.4M
-
Which has Higher Returns SLS or SVRA?
Savara, Inc. has a net margin of -- compared to SELLAS Life Sciences Group, Inc.'s net margin of --. SELLAS Life Sciences Group, Inc.'s return on equity of -74.67% beat Savara, Inc.'s return on equity of -80.59%.
Company Gross Margin Earnings Per Share Invested Capital SLSSELLAS Life Sciences Group, Inc.-- -$0.05 $71.9M SVRASavara, Inc.-- -$0.13 $233M -
What do Analysts Say About SLS or SVRA?
SELLAS Life Sciences Group, Inc. has a consensus price target of $8.67, signalling upside risk potential of 109.85%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 94.47%. Given that SELLAS Life Sciences Group, Inc. has higher upside potential than Savara, Inc., analysts believe SELLAS Life Sciences Group, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLSSELLAS Life Sciences Group, Inc.2 0 0 SVRASavara, Inc.6 0 0 -
Is SLS or SVRA More Risky?
SELLAS Life Sciences Group, Inc. has a beta of 2.225, which suggesting that the stock is 122.467% more volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.316, suggesting its less volatile than the S&P 500 by 68.412%.
-
Which is a Better Dividend Stock SLS or SVRA?
SELLAS Life Sciences Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SELLAS Life Sciences Group, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLS or SVRA?
SELLAS Life Sciences Group, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. SELLAS Life Sciences Group, Inc.'s net income of -$7.7M is higher than Savara, Inc.'s net income of -$32.2M. Notably, SELLAS Life Sciences Group, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SELLAS Life Sciences Group, Inc. is -- versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLSSELLAS Life Sciences Group, Inc.-- -- -- -$7.7M SVRASavara, Inc.-- -- -- -$32.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 4
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 4
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 4
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
